CD4 and non-small cell lung carcinoma: Among 12 HIV-infected patients with advanced NSCLC treated with second-line nivolumab, a favorable clinical outcome (7/12 disease control with 3 partial responses and 4 disease stabilizations), without clinically meaningful side effects (except one case of neurosyphilis) and neither a relevant impact on HIV viral load nor CD4+/CD8+ cell count were reported.